Role of adenine nucleotide translocator 1 in mtDNA maintenance
J Kaukonen, JK Juselius, V Tiranti, A Kyttälä… - Science, 2000 - science.org
Autosomal dominant progressive external ophthalmoplegia is a rare human disease that
shows a Mendelian inheritance pattern, but is characterized by large-scale mitochondrial DNA (…
shows a Mendelian inheritance pattern, but is characterized by large-scale mitochondrial DNA (…
[PDF][PDF] Genetic variability overrides the impact of parental cell type and determines iPSC differentiation potential
A Kyttälä, R Moraghebi, C Valensisi, J Kettunen… - Stem cell reports, 2016 - cell.com
Reports on the retention of somatic cell memory in induced pluripotent stem cells (iPSCs)
have complicated the selection of the optimal cell type for the generation of iPSC biobanks. To …
have complicated the selection of the optimal cell type for the generation of iPSC biobanks. To …
Interconnections of CLN3, Hook1 and Rab proteins link Batten disease to defects in the endocytic pathway
…, H Maunu, I Järvelä, A Kyttälä… - Human molecular …, 2004 - academic.oup.com
The endosomal/lysosomal transmembrane protein CLN3 is mutated in the Batten disease (juvenile
neuronal ceroid lipofuscinosis, JNCL). However, the molecular mechanism of JNCL …
neuronal ceroid lipofuscinosis, JNCL). However, the molecular mechanism of JNCL …
Two motifs target Batten disease protein CLN3 to lysosomes in transfected nonneuronal and neuronal cells
Batten disease is a neurodegenerative disorder resulting from mutations in CLN3, a polytopic
membrane protein, whose predominant intracellular destination in nonneuronal cells is the …
membrane protein, whose predominant intracellular destination in nonneuronal cells is the …
Palmitoyl protein thioesterase (PPT) localizes into synaptosomes and synaptic vesicles in neurons: implications for infantile neuronal ceroid lipofuscinosis (INCL)
M Lehtovirta, A Kyttälä, EL Eskelinen… - Human molecular …, 2001 - academic.oup.com
A deficiency of palmitoyl protein thioesterase (PPT) leads to the neurodegenerative disease
infantile neuronal ceroid lipofuscinosis (INCL), which is characterized by an almost …
infantile neuronal ceroid lipofuscinosis (INCL), which is characterized by an almost …
The neuronal ceroid lipofuscinosis CLN8 membrane protein is a resident of the endoplasmic reticulum
L Lonka, A Kyttälä, S Ranta, A Jalanko… - Human molecular …, 2000 - academic.oup.com
Progressive epilepsy with mental retardation (EPMR) is a new member of the neuronal
ceroid lipofuscinoses (NCLs). The CLN8 gene underlying EPMR was recently identified. It …
ceroid lipofuscinoses (NCLs). The CLN8 gene underlying EPMR was recently identified. It …
[HTML][HTML] Novel interactions of CLN5 support molecular networking between Neuronal Ceroid Lipofuscinosis proteins
…, C Heine, ML Schmiedt, T Sipilä, A Jalanko, A Kyttälä - BMC cell biology, 2009 - Springer
Background Neuronal ceroid lipofuscinoses (NCLs) comprise at least eight genetically
characterized neurodegenerative disorders of childhood. Despite of genetic heterogeneity, the …
characterized neurodegenerative disorders of childhood. Despite of genetic heterogeneity, the …
Defective intracellular transport of CLN3 is the molecular basis of Batten disease (JNCL)
…, M Lehtovirta, R Tikkanen, A Kyttälä… - Human molecular …, 1999 - academic.oup.com
Batten disease [juvenile-onset neuronal ceroid lipofuscinosis (JNCL)], the most common
progressive encephalopathy of childhood, is caused by mutations in a novel lysosomal …
progressive encephalopathy of childhood, is caused by mutations in a novel lysosomal …
Neuronal ceroid lipofuscinosis protein CLN3 interacts with motor proteins and modifies location of late endosomal compartments
K Uusi-Rauva, A Kyttälä, R van der Kant, J Vesa… - Cellular and Molecular …, 2012 - Springer
CLN3 is an endosomal/lysosomal transmembrane protein mutated in classical juvenile
onset neuronal ceroid lipofuscinosis, a fatal inherited neurodegenerative lysosomal storage …
onset neuronal ceroid lipofuscinosis, a fatal inherited neurodegenerative lysosomal storage …
[HTML][HTML] Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma
…, A Fayzullin, CJ Sandberg, S Potdar, A Kyttälä… - BMC cancer, 2019 - Springer
Background A major barrier to effective treatment of glioblastoma (GBM) is the large
intertumoral heterogeneity at the genetic and cellular level. In early phase clinical trials, patient …
intertumoral heterogeneity at the genetic and cellular level. In early phase clinical trials, patient …